Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Danlos, F. X.; Voisin, A. L.; Dyevre, V.; Michot, J. M.; Routier, E.; Taillade, L.; Champiat, S.; Aspeslagh, S.; Haroche, J.; Albiges, L.; Massard, C.; Girard, N.; Dalle, S.; Besse, B.; Laghouati, S.; Soria, J. C.; Mateus, C.; Robert, C.; Lanoy, E.; Marabelle, A.; Lambotte, O.. Eur J Cancer. 2018; 21-29: p.21-29. doi:10.1016/j.ejca.2017.12.008
Article